de Citigroup Ligand Pharmaceuticals LGND Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 21.1 M | Comprar |
66,639
+45,045
| +209% | +USD 10.6 M | 0.01% | 1145 |
|
|
2026
Q1 | USD 4.31 M | Comprar |
21,594
+3,302
| +18% | +USD 653 k | ﹤0.01% | 2081 |
|
|
2025
Q4 | USD 3.46 M | Vender |
18,292
-3,095
| -14% | -USD 595 k | ﹤0.01% | 2283 |
|
|
2025
Q3 | USD 3.79 M | Vender |
21,387
-8,287
| -28% | -USD 1.23 M | ﹤0.01% | 2182 |
|
|
2025
Q2 | USD 3.37 M | Vender |
29,674
-16
| -0.1% | -USD 1.71 k | ﹤0.01% | 2229 |
|
|
2025
Q1 | USD 3.12 M | Comprar |
29,690
+1,702
| +6% | +USD 192 k | ﹤0.01% | 2324 |
|
|
2024
Q4 | USD 3 M | Comprar |
27,988
+2,408
| +9% | +USD 272 k | ﹤0.01% | 2457 |
|
|
2024
Q3 | USD 2.56 M | Comprar |
25,580
+11,107
| +77% | +USD 1.12 M | ﹤0.01% | 2448 |
|
|
2024
Q2 | USD 1.22 M | Comprar |
14,473
+1,211
| +9% | +USD 96.4 k | ﹤0.01% | 2761 |
|
|
2024
Q1 | USD 969 k | Comprar |
13,262
+816
| +7% | +USD 60.2 k | ﹤0.01% | 3049 |
|
|
2023
Q4 | USD 889 k | Comprar |
12,446
+3,669
| +42% | +USD 217 k | ﹤0.01% | 2925 |
|
|
2023
Q3 | USD 526 k | Vender |
8,777
-7,295
| -45% | -USD 480 k | ﹤0.01% | 3018 |
|
|
2023
Q2 | USD 1.16 M | Comprar |
16,072
+3,676
| +30% | +USD 276 k | ﹤0.01% | 2722 |
|
|
2023
Q1 | USD 912 k | Vender |
12,396
-572
| -4% | -USD 40.7 k | ﹤0.01% | 2633 |
|
|
2022
Q4 | USD 866 k | Vender |
12,968
-54,938
| -81% | -USD 3.57 M | ﹤0.01% | 2746 |
|
|
2022
Q3 | USD 3.65 M | Comprar |
67,906
+9,174
| +16% | +USD 539 k | ﹤0.01% | 1731 |
|
|
2022
Q2 | USD 3.27 M | Comprar |
58,732
+20,359
| +53% | +USD 1.16 M | ﹤0.01% | 1773 |
|
|
2022
Q1 | USD 2.69 M | Vender |
38,373
-29,171
| -43% | -USD 2.12 M | ﹤0.01% | 2105 |
|
|
2021
Q4 | USD 6.51 M | Comprar |
67,544
+10,267
| +18% | +USD 948 k | ﹤0.01% | 1653 |
|
|
2021
Q3 | USD 4.98 M | Comprar |
57,277
+893
| +2% | +USD 69.1 k | ﹤0.01% | 1836 |
|
|
2021
Q2 | USD 4.62 M | Comprar |
56,384
+10,064
| +22% | +USD 837 k | ﹤0.01% | 1962 |
|
|
2021
Q1 | USD 4.4 M | Comprar |
46,320
+37,536
| +427% | +USD 3.55 M | ﹤0.01% | 1871 |
|
|
2020
Q4 | USD 545 k | Comprar |
8,784
+5,168
| +143% | +USD 295 k | ﹤0.01% | 4128 |
|
|
2020
Q3 | USD 215 k | Vender |
3,616
-23,548
| -87% | -USD 1.61 M | ﹤0.01% | 4563 |
|
|
2020
Q2 | USD 1.9 M | Vender |
27,164
-13,656
| -33% | -USD 866 k | ﹤0.01% | 2870 |
|
|
2020
Q1 | USD 1.85 M | Comprar |
40,820
+15,962
| +64% | +USD 905 k | ﹤0.01% | 2550 |
|
|
2019
Q4 | USD 1.62 M | Vender |
24,858
-832
| -3% | -USD 55.6 k | ﹤0.01% | 3236 |
|
|
2019
Q3 | USD 1.6 M | Comprar |
25,690
+2,490
| +11% | +USD 156 k | ﹤0.01% | 3120 |
|
|
2019
Q2 | USD 1.65 M | Vender |
23,200
-9,041
| -28% | -USD 666 k | ﹤0.01% | 3077 |
|
|
2019
Q1 | USD 2.53 M | Vender |
32,241
-66,768
| -67% | -USD 5.06 M | ﹤0.01% | 2434 |
|
|
2018
Q4 | USD 8.38 M | Comprar |
99,009
+57,022
| +136% | +USD 6.08 M | 0.01% | 1390 |
|
|
2018
Q3 | USD 7.19 M | Comprar |
41,987
+30,473
| +265% | +USD 4.59 M | 0.01% | 1524 |
|
|
2018
Q2 | USD 1.49 M | Vender |
11,514
-31,531
| -73% | -USD 3.52 M | ﹤0.01% | 2962 |
|
|
2018
Q1 | USD 4.44 M | Vender |
43,045
-15,219
| -26% | -USD 1.51 M | ﹤0.01% | 1870 |
|
|
2017
Q4 | USD 4.98 M | Comprar |
58,264
+8,311
| +17% | +USD 720 k | ﹤0.01% | 1841 |
|
|
2017
Q3 | USD 4.24 M | Vender |
49,953
-1,784
| -3% | -USD 141 k | ﹤0.01% | 1919 |
|
|
2017
Q2 | USD 3.92 M | Comprar |
51,737
+4,035
| +8% | +USD 282 k | ﹤0.01% | 1917 |
|
|
2017
Q1 | USD 3.15 M | Vender |
47,702
-88,090
| -65% | -USD 5.8 M | ﹤0.01% | 2043 |
|
|
2016
Q4 | USD 8.61 M | Comprar |
135,792
+111,157
| +451% | +USD 7.01 M | 0.01% | 1311 |
|
|
2016
Q3 | USD 1.57 M | Comprar |
24,635
+14,972
| +155% | +USD 1.1 M | ﹤0.01% | 2750 |
|
|
2016
Q2 | USD 719 k | Vender |
9,663
-11,208
| -54% | -USD 832 k | ﹤0.01% | 3273 |
|
|
2016
Q1 | USD 1.39 M | Vender |
20,871
-41,793
| -67% | -USD 2.54 M | ﹤0.01% | 2939 |
|
|
2015
Q4 | USD 4.24 M | Comprar |
62,664
+2,712
| +5% | +USD 167 k | ﹤0.01% | 1844 |
|
|
2015
Q3 | USD 3.2 M | Comprar |
59,952
+57,839
| +2,737% | +USD 3.51 M | ﹤0.01% | 2051 |
|
|
2015
Q2 | USD 133 k | Vender |
2,113
-710
| -25% | -USD 38.7 k | ﹤0.01% | 4780 |
|
|
2015
Q1 | USD 136 k | Vender |
2,823
-17,683
| -86% | -USD 678 k | ﹤0.01% | 4807 |
|
|
2014
Q4 | USD 681 k | Comprar |
20,506
+4,551
| +29% | +USD 148 k | ﹤0.01% | 3554 |
|
|
2014
Q3 | USD 468 k | Comprar |
15,955
+14,506
| +1,001% | +USD 482 k | ﹤0.01% | 3586 |
|
|
2014
Q2 | USD 56 k | Vender |
1,449
-460
| -24% | -USD 18.7 k | ﹤0.01% | 5090 |
|
|
2014
Q1 | USD 80 k | Vender |
1,909
-8,889
| -82% | -USD 371 k | ﹤0.01% | 5182 |
|
|
2013
Q4 | USD 355 k | Comprar |
10,798
+4,307
| +66% | +USD 140 k | ﹤0.01% | 4128 |
|
|
2013
Q3 | USD 175 k | Comprar |
6,491
+6,201
| +2,138% | +USD 174 k | ﹤0.01% | 4268 |
|
|
2013
Q2 | USD 7 k | Comprar |
+290
| Nuevas | +USD 5.22 k | ﹤0.01% | 6229 |
|
Otros fondos que tienen LGND en su cartera
Posición de Citigroup en LGND: resumen de T2 2026
Citigroup aumentó su participación en Ligand Pharmaceuticals (LGND) en 209% durante T2 2026, al comprar aproximadamente USD 10.6 M y elevar la posición a 66,639 acciones con un valor de USD 21.1 M. La posición representa 0.01% de la cartera y ocupa el puesto #1145.
Citigroup reportó por primera vez una posición en LGND en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 418 fondos que sigue Wall St. Rank mantienen una posición en LGND.
- Al cierre de T2 2026, Citigroup tenía 66,639 acciones de Ligand Pharmaceuticals con un valor de USD 21.1 M.
- Citigroup compró 45,045 acciones de Ligand Pharmaceuticals en T2 2026, por un monto estimado de USD 10.6 M.
- Ligand Pharmaceuticals representó 0.01% de la cartera de Citigroup en T2 2026 y fue su posición número 1145.
- Citigroup reportó por primera vez una posición en Ligand Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 418 fondos que sigue Wall St. Rank tenían Ligand Pharmaceuticals en cartera.
Según el Informe 13F de Citigroup correspondiente a T2 2026, presentado el 3 ago 2026.